Valproic acid (VPA) increases SMN expression in SMA patient-derived cell lines as well as in SMA patients probably through its action as a histone deacetylase (HDAC) inhibitor [20]–[26]. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.